Status:
ACTIVE_NOT_RECRUITING
Circulating Tumour DNA (ctDNA) as a Prognostic and Predictive Marker in Colorectal Cancer - a Pilot Study
Lead Sponsor:
Anna Martling
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
In clinical practice, there are currently no biomarkers that can guide colorectal cancer treatment in the primary and curative setting. Improved biomarker-based adjuvant treatments would be of greates...
Eligibility Criteria
Inclusion
- Colon or rectal cancer tumor stage I-III planned for radical surgery
- Clean Colonoscopy or Computed Tomography (CT) colon within 3 months preoperatively or postoperatively but before randomization
- Patient able to understand and sign written informed consent
Exclusion
- Distant metastases
- Other cancers (excluding colorectal cancer or other skin cancer than melanoma) within 3 years from screening
- Significant medical illness that would interfere with study participation
- Pregnancy or breastfeeding females
- Current participation in another clinical trial that will be in conflict with the present study
- Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude, inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study
Key Trial Info
Start Date :
October 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04726800
Start Date
October 1 2020
End Date
December 1 2024
Last Update
February 20 2024
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Akershus Univeristy Hospital
Oslo, Norway
2
Sahlgrenska University Hospital
Gothenburg, Sweden
3
Skaraborg Hospital
Skövde, Sweden
4
Capio Sankt Göran Hospital
Stockholm, Sweden